Daklinza (daclatasvir) / BMS - LARVOL DELTA

Third Time's the Charm: Virologic Suppression After 2 Consecutive DAA Failures in Chronic Hepatitis C (ACG 2026) - "Introduction: Direct-acting antivirals achieve sustained virologic response (SVR) in over 95% of patients with chronic hepatitis C virus (HCV) infection, so sequential failure of multiple regimens is rare, and evidence guiding retreatment after sofosbuvir/velpatasvir/voxilaprevir failure is limited and extrapolated from small studies.[1] We present a non-cirrhotic genotype 1a patient with an NS5A L31M resistance-associated variant (RAV) who failed two sequential regimens but achieved on-treatment suppression with an extended course plus ribavirin...L31M was classified as conferring possible resistance to daclatasvir, elbasvir, ledipasvir, and ombitasvir, but no determinable impact on velpatasvir or pibrentasvir...Third, the recommendation for this extended regimen after voxilaprevir failure rests on a retrospective study of only four patients, so each real-world case adds to a thin evidence base. Suppression after two failed courses suggests extended duration and..."

Cardiovascular • Fibrosis • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation • Orthopedics • Portal Hypertension

Activated Sludge in the Bioremediation of Water Containing SARS-CoV-2 Antivirals. (PubMed, J Xenobiot) - "This study evaluates the removal percentages, kinetic mechanisms, and toxicity profiles of six SASs, daclatasvir (DCV), darunavir (DRV), favipiravir (FAV), lopinavir (LOP), remdesivir (REM), and ritonavir (RIT), using activated sludge. Perturbation analysis showed that all tested factors have a distinct influence on process performance. These established kinetic trends should support further investigations into advanced biological wastewater treatment methods and precise ecotoxicity profiling of emerging biotransformation products."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Are Direct-Acting Antivirals Effective and Safe for Hepatitis C Patients with Arterial Hypertension? Evidence from a Large Retrospective Real-World Study. (PubMed, Viruses) - "Predictors of failure included genotype 3, decompensated liver function, cirrhosis, thrombocytopenia, and treatment with asunaprevir + daclatasvir. Although not directly evaluated, the overall safety outcomes suggest that potential drug-drug interactions with antihypertensive therapies are unlikely to have a major clinical impact in routine practice. This study highlights the safety and efficacy of DAAs in AH patients and emphasizes the importance of early HCV detection and treatment in this population."

Clinical • Journal • Real-world evidence • Retrospective data • Cardiovascular • Fatigue • Fibrosis • Genetic Disorders • Hematological Disorders • Hepatitis C • Hepatocellular Cancer • Hepatology • Hypertension • Immunology • Infectious Disease • Inflammation • Obesity • Oncology • Pulmonary Arterial Hypertension • Solid Tumor • Thrombocytopenia

Elevation of anticancer drug-induced cytotoxicity by velpatasvir through downregulation of claudin-14 expression in human colorectal cancer cells. (PubMed, Eur J Pharmacol) - "CLDN14 expression was not decreased by other NS5A inhibitors, including ledipasvir, pibrentasvir, and daclatasvir...Consequently, VEL promoted the intracellular accumulation of doxorubicin and significantly potentiated its cytotoxic effects. Moreover, VEL enhanced the antitumor efficacy of other chemotherapeutic agents, including oxaliplatin and SN-38, the active metabolite of irinotecan. These findings suggest that VEL enhances anticancer drug sensitivity in CRC cells through lysosome-dependent downregulation of CLDN14 protein and suppression of Nrf2-dependent oxidative stress responses."

Journal • Colorectal Cancer • Hepatitis C • Infectious Disease • Oncology • Solid Tumor • NFE2L2

Serum albumin nanoparticle systems for encapsulation and sustained release of antiviral drugs. (PubMed, J Microencapsul) - "In the present study, bovine serum albumin (BSA) nanoparticles were prepared using desolvation method and explored as carriers for antiviral drugs like remdesivir, molnupiravir, hydroxychloroquine, and daclatasvir. Encapsulation efficiency remained nearly constant across formulations F-1 to F-4, suggesting early saturation of drug-protein interaction sites and efficient loading at lower BSA levels. Results from formulation F-2 indicated that drug release patterns were influenced more by the intrinsic physicochemical characteristics of the drug than by nanoparticle characteristics."

Journal • Infectious Disease • Novel Coronavirus Disease

Efficacy of 12 Weeks Versus 24 Weeks Treatment of Directly Acting Antiviral Therapy in Patients With Hepatitis C Related Chronic Liver Disease (clinicaltrials.gov) - P=N/A | N=192 | Completed | Sponsor: Indus Hospital and Health Network

New trial • Hepatitis C • Hepatology • Infectious Disease • Inflammation • AFP

REAL-WORLD PREDICTORS OF TREATMENT FAILURE AND NS5A RESISTANCE SELECTION IN GENOTYPE 3 HEPATITIS C: A MULTICENTER COHORT WITH LONGITUDINAL SEQUENCING AND IN-SILICO MODELLING (ISPOR 2026) - "In GT3 infection, DAA failure is driven by cirrhosis and prior NS5A exposure. National Programs should implement resistance testing at failure and use resistance-guided, higher-barrier retreatment rather than recycling prior regimens."

Clinical • Real-world • Real-world evidence • Fibrosis • Genetic Disorders • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation • Obesity

FRI-STC: Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC (clinicaltrials.gov) - P3 | N=150 | Completed | Sponsor: National Hepatology & Tropical Medicine Research Institute | Unknown status ➔ Completed

Trial completion • Hepatitis C • Hepatocellular Cancer • Infectious Disease • Oncology • Solid Tumor

Anti-COVID-19 activity and simple HPLC method for concurrent detection of repurposed drugs in novel binary mixtures. (PubMed, AMB Express) - No abstract available

Journal • Infectious Disease • Novel Coronavirus Disease

Repurposing antiviral agents against mucormycosis. (PubMed, PLoS One) - "Four candidates, IMB-301, U18666A, BLT-1, and obefazimod, showed potent in vitro effects, with three sustaining growth suppression comparable to AmB for up to 48 h in time-kill assays. The hepatitis C antivirals daclatasvir (DAC) and velpatasvir (VEL) demonstrated strong synergy with AmB across Mucorales isolates, lowering AmB MICs by 4- to 32-fold (ΣFICI 32 indicated favorable safety margins. These findings highlight antiviral repurposing as a promising strategy to expand treatment options for mucormycosis and support further translational development."

Journal • Hepatitis C • Infectious Disease • Inflammation

A Decade Long, Real-life Experience of Sofosbuvir-based Regimen Use for Hepatitis C Treatment in People With End-stage Renal Disease. (PubMed, J Clin Exp Hepatol) - "They were treated with full-dose SOF (400 mg) in combination with either velpatasvir (VEL) 100 mg or daclatasvir (DAC) 60 mg. After achieving SVR12, eight and one patient had second and third episodes of HCV re-infections after 8 (4-13.5) months and 6 months, respectively, and five of them achieved SVR12 following retreatment. Sofosbuvir in combination with DAC or VEL are highly and equally effective against HCV in patients with eGFR below 30 mL/min."

Journal • Chronic Kidney Disease • Fibrosis • Hepatitis C • Immunology • Infectious Disease • Inflammation • Nephrology • Renal Disease

Repurposing of FDA-Approved Antiviral Drugs Against Monkeypox Virus: Comparative In Vitro Screening and Structure Based In Silico Studies. (PubMed, Pharmaceuticals (Basel)) - "Twenty-three FDA-approved drugs, including Abacavir, Acyclovir, Amantadine, Chloroquine, Daclatasvir, Dolutegravir, Entecavir, Favipiravir, Hydroxychloroquine, Lamivudine, Molnupiravir, Nevirapine, Oseltamivir, Penciclovir, Remdesivir, Ribavirin, Sofosbuvir, Tenofovir, Valaciclovir, Valganciclovir, Velpatasvir, Zanamivir, and Zidovudine, were screened for potential anti-monkeypox activity in vitro...The employed computational methods indicate that remdesivir demonstrated superior binding patterns with elevated scores and stable complexes throughout the simulation. Our findings showed that Remdesivir therapeutic compound is potent against the tested strain of MPXV, and exhibited a robust binding affinity for Thymidylate Kinase, A42R Profilin-Like Protein, and VACV D13 enzymes, and thus may potentially be utilized as antiviral for the treatment of monkeypox virus."

FDA event • Journal • Preclinical • Infectious Disease

Genetic Characterization of Hepatitis C Virus Among People Who Use Crack Cocaine: A Study Conducted on the Brazilian Amazon Coast. (PubMed, Pathogens) - "The high prevalence of HCV infection, predominantly subtype 1b, and significant levels of resistance are very concerning. This demonstrates the urgent need for targeted public health interventions to expand access to testing, treatment, and effective antiviral therapy in this vulnerable population of the Brazilian Amazon."

Journal • Hepatitis C • Infectious Disease • Inflammation

Evaluating long-term outcomes of direct-acting antiviral therapy in chronic hepatitis C: A retrospective study. (PubMed, Medicine (Baltimore)) - "Treatment included asunaprevir and daclatasvir in 46.2%, with 46.2% receiving a 12-week regimen. DAA treatment effectively treats CHC and reduces liver fibrosis. However, further research is warranted to better understand and predict the development of HCC."

Journal • Observational data • Retrospective data • Fibrosis • Gastroenterology • Hepatitis C • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis • Oncology • Solid Tumor

Antifibrotic Efficacy of Daclatasvir Against Pulmonary Fibrosis: Insights From Network Pharmacology, Molecular Docking, Dynamics, and Preclinical Evaluations. (PubMed, Chem Biodivers) - "The present study evaluated DAC in a bleomycin (BLM)-induced PF rat model, integrating network pharmacology, molecular docking, and molecular dynamics (MD) simulation to decipher its mechanisms...PCA analyses also confirmed complex stability, comparable to known inhibitors vorinostat and mocetinostat...Interestingly, a higher dose (12.4 mg/kg/day) showed reduced efficacy and increased lung index, indicating dose sensitivity. These findings suggest that DAC possesses dose-dependent antifibrotic activity in PF and warrants further exploration as a repurposable therapeutic candidate."

Journal • Preclinical • Fibrosis • Hepatitis C • Immunology • Infectious Disease • Inflammation • Pulmonary Disease • Respiratory Diseases • HDAC2 • HIF1A

In silico screening of potential FGF2 inhibitors for cancer therapy. (PubMed, In Silico Pharmacol) - "Molecular docking study showed Elbasvir (1) to exhibit the strongest binding affinity (-8.1 kcal/mol), followed by Velpatasvir (2) (-7.6 kcal/mol), Daclatasvir (3) (-7.5 kcal/mol), Ritonavir (4) (-6.2 kcal/mol), Paliperidone Palmitate (5) (-5.9 kcal/mol), Saralasin (6) (-5.4 kcal/mol), Nystatin (8) (-5.2 kcal/mol), and Cobicistat (-5.1 kcal/mol)...Overall, the study provides mechanistic insights into the molecular interactions between FGF2 and these candidate drugs, highlighting the promising potential of compounds 1-6 and 8 for subsequent in vitro validation in cancer therapeutics. The online version contains supplementary material available at 10.1007/s40203-025-00495-2."

Journal • Acute Myelogenous Leukemia • Brain Cancer • Breast Cancer • Gastric Cancer • Glioblastoma • Hematological Malignancies • Leukemia • Lung Cancer • Nasopharyngeal Carcinoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • FGF2 • FGFR

Decentralised Hepatitis C Management: A Simplified, Integrated Model of Care in a Primary Health Centre in Pakistan, August 2022-June 2023. (PubMed, J Viral Hepat) - "Viraemic patients were treated with 12- or 24-week regimens of sofosbuvir (400 mg) and daclatasvir (60 mg), depending on the fibrosis degree. The model appears feasible in terms of patient-level outcomes, though broader operational feasibility-including resources and scalability-was not formally assessed. Remaining barriers to treatment initiation and follow-up need to be addressed to advance national HCV elimination goals."

Journal • Fibrosis • Hepatitis C • Immunology • Infectious Disease • Inflammation

PSMD14-mediated PFKFB2 deubiquitination activates H3K27 lactylation to drive cancer stemness in gastric adenocarcinoma. (PubMed, Cell Death Differ) - "Notably, high-throughput screening of FDA-approved drugs reveals that Daclatasvir (DCV) exhibits high binding affinity for PSMD14 protein, disrupts the PSMD14-PFKFB2 interaction, reduces PFKFB2 activity and tumor burden. Collectively, our findings are the first to elucidate a positive feedback loop existing between PSMD14 and glycolysis in GAC progression, suggesting that PSMD14 blockade may represent a potential therapeutic approach for GAC."

Journal • Gastric Adenocarcinoma • Gastric Cancer • Oncology • Solid Tumor • Targeted Protein Degradation • PSMD14 • SOX9

Analysis of genetic polymorphisms and drug resistance mutations in the NS5 region of HCV genome (Flasuviricetes: Amarillovirales: Flaviviridae: Hepacivirus C) in samples obtained in 2022-2023 from HIV-infected treatment-naive residents of Altai Krai (PubMed, Vopr Virusol) - "Our results may indirectly indicate the increasing proportion of the HCV subtype 3a in the hepatitis C epidemic in the Altai Territory. Our data on DR and polymorphisms should be taken into account in antiviral therapy of patients."

Journal • Hepatitis C • Human Immunodeficiency Virus • Infectious Disease • Inflammation

SOFOSBUVIR BASED REGIMENS ARE EFFECTIVE FOR HEPATITIS C TREATMENT IN PATIENTS WITH END-STAGE RENAL DISEASE IN REAL-LIFE SETTING (AASLD 2025) - "Sofosbuvir in combination with daclatasvir or velpatasvir are highly and equally effective against HCV in CKD patients with eGFR below 30 mL/min."

Clinical • Chronic Kidney Disease • Fibrosis • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation • Nephrology • Renal Disease

IN VITRO MODEL OF AURKB EXPRESSION LEVELS REGULATION MEDIATED BY SOFOSBUVIR TREATMENT (AASLD 2025) - " Cultures of Huh7 and Huh7.5 hepatoma cell lines were treated with SOF (C22H29N3FO9P) or daclatasvir (DCV) (BMS-790052) at different doses...All SOF-induced effects were reversed in the presence of AZD1152, an inhibitor of AURKB activity, confirming that they were exerted through the AURKB pathway... These results suggest that SOF can induce cell cycle modifications through AURKB activation in in vitro cell models. The effect of these changes in vivo (hepatitis C patients treated with SOF) should be analysed, taking into account that HCV eradication may induce an increase in AURKB per se, due to the inhibitory effect that the viral core protein exerts on AURKB activity."

Preclinical • Hepatitis C • Hepatocellular Cancer • Hepatology • Infectious Disease • Liver Cancer • Solid Tumor • AURKB • DUSP1 • EGFR • PDGFRB

Assessment of direct-acting antiviral treatment outcomes in patients with chronic hepatitis C infected with various HCV genotypes: Insights from a real-world cohort in West Bengal, India. (PubMed, BMC Infect Dis) - "This study highlights genotype-specific variations in treatment response, with GT-3b exhibiting lower treatment response which highlights the need to decipher the reasons behind treatment failure for future therapeutic management."

Journal • Real-world evidence • Retrospective data • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Novel Coronavirus Disease

Smartphone-assisted EY@ MOF-5-based dual-emission fluorescent sensor for rapid on-site detection of daclatasvir and nitenpyram (ACS-Fall 2025) - "Then, a smartphone-integrated sensing system is introduced for on-site, real-time, and quantitative analysis of DCT and NTP. The smartphone-assisted intelligent sensing method manifests promising results for DCT and NTP monitoring in biological and food samples, demonstrating its promising potential for the on-site detection of biologically and environmentally significant analytes."

Repurposing Daclatasvir for MASLD Therapy - A Promising Step Forward with Challenges Ahead. (PubMed, J Lipid Res) - No abstract available

Journal • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease

Impact of Resistance Associated Substitutions and Predictors of Treatment Failure Following Direct-acting Antiviral Therapy in a Viral Hepatitis C Elimination Cohort. (PubMed, J Clin Exp Hepatol) - P=N/A | "The National Viral Hepatitis Control Program (NVHCP) has a cure rate of 91.6% when using direct-acting antivirals (DAAs)-sofosbuvir with an NS5A inhibitor (ledipasvir, daclatasvir or velpatasvir) ± ribavirin in the Punjab hub-and-spoke model of hepatitis C virus (HCV) elimination...Among these Y93K, L30R, G30 H/R confer resistance to velpatasvir; such patients received retreatment with voxilaprevir-containing regimens...RAS do not appear to be a primary factor for treatment failure in a public health setting. NCT03488485 available from https://clinicaltrials.gov/study/NCT03488485."

Journal • Fibrosis • Hepatitis B • Hepatitis C • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammation